SXTCNasdaqPharmaceutical PreparationsFiscal year ends March 31
China SXT Pharmaceuticals, Inc.
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 1, 2026
$0.11+0.05 (+71.08%)
Close on Oct 19, 2026
Market cap
–
P/E (TTM)
–
Dividend yield
–
China SXT Pharmaceuticals statistics
Financials through Mar 31, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
Measure
China SXT Pharmaceuticals
Industry median
Market Cap
$106.54K
$164.85M
Enterprise Value
-$27.07M
$87.06M
PS Ratio
0.09
3.60
PB Ratio
0.00
2.03
P/TBV Ratio
0.00
2.31
Enterprise value
Measure
China SXT Pharmaceuticals
Industry median
EV / Sales
-23.79
2.43
Income (trailing twelve months)
Measure
China SXT Pharmaceuticals
Industry median
Revenue
$1.14M
$57.94M
Gross Profit
$248.70K
$90.47M
Operating Income
-$7.12M
-$21.44M
Pretax Income
-$6.21M
-$14.45M
Net Income
-$6.21M
-$22.46M
EBITDA
-$7.05M
-$16.91M
EPS (Diluted)
-$9.13
-$0.83
Margins
Measure
China SXT Pharmaceuticals
Industry median
Gross Margin
21.9%
52.3%
Operating Margin
-625.9%
-44.5%
Pretax Margin
-545.2%
-13.0%
Profit Margin
-545.2%
-39.2%
EBITDA Margin
-619.4%
-31.3%
Returns
Measure
China SXT Pharmaceuticals
Industry median
Return on Equity (ROE)
-27.5%
-53.1%
Return on Assets (ROA)
-22.0%
-41.0%
Return on Invested Capital (ROIC)
-1657.2%
-32.0%
Return on Capital Employed (ROCE)
-23.4%
-37.8%
Growth
Measure
China SXT Pharmaceuticals
Industry median
Revenue Growth (YoY)
-34.6%
6.01%
Revenue Growth (3Y CAGR)
-16.7%
2.25%
Revenue Growth (5Y CAGR)
-24.9%
6.42%
Balance sheet
Measure
China SXT Pharmaceuticals
Industry median
Cash & Short-Term Investments
$28.18M
$62.42M
Total Debt
$999.57K
$120.13M
Net Cash (Debt)
$27.18M
$15.68M
Net Cash Per Share
$28.37
$0.66
Equity (Book Value)
$29.71M
$48.79M
Book Value Per Share
$31.01
$1.36
Tangible Book Value
$29.70M
$23.06M
Working Capital
$30.16M
$75.77M
Financial position
Measure
China SXT Pharmaceuticals
Industry median
Current Ratio
7.93
3.30
Quick Ratio
6.69
2.39
Debt / Equity
0.03
0.51
Interest Coverage
-113.13
-7.12
Cash flow (trailing twelve months)
Measure
China SXT Pharmaceuticals
Industry median
Operating Cash Flow
-$4.02M
-$12.35M
Efficiency
Measure
China SXT Pharmaceuticals
Industry median
Asset Turnover
0.04
0.38
Inventory Turnover
1.11
2.67
Revenue Per Employee
$20.32K
$398.96K
Profits Per Employee
-$110.81K
-$703.34K
Employee Count
56
74
Dividends and yields
Measure
China SXT Pharmaceuticals
Industry median
Earnings Yield
-5824.3%
-22.7%
Shares
Measure
China SXT Pharmaceuticals
Industry median
Shares Outstanding
958,077
58,179,650
Shares Change (YoY)
7062.5%
11.1%
Float
958,073
49,173,100
Shares Held by Insiders
0.00%
11.6%
Scores
Measure
China SXT Pharmaceuticals
Industry median
Altman Z-Score
-0.97
-0.24
Piotroski F-Score
3
4
Beneish M-Score
-3.57
-2.62
Calculated by StockData from China SXT Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.